Regulatory BMS’ Sotyktu secures EC approval for psoriatic arthritis Pharmaceutical TechnologyBMS has secured approval from the European Commission for Sotyktu (deucravacitinib) to treat active psoriatic arthritis (PsA).Immunology & InflammationRead full story pharminent May 11, 2026 (Last updated: May 11, 2026) Pharmaceutical Technology BMS has secured approval from the European Commission for Sotyktu (deucravacitinib) to treat active psoriatic arthritis (PsA). Immunology & Inflammation Read full story Post navigation Previous: Pulsesight reports positive phase 1 data for PST611 in dry AMDNext: Deal finally unlocks NHS access to ITF’s Duchenne drug Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
